Jack Msonkho

models@cambiocds.com

@Cambio CDS

Provides prognostic information for patients. Suggests patients who may need closer follow up. Allows for stratification of patients on clinical trials potentially evaluating newer, targeted myeloma therapies. Does not require FISH studies, cytogenetic, or MRI bone studies, which may add further discrimination but are not widely available; hence, generalizability is preserved in settings with limited availability of these studies

The guideline works by evaluating the average % from bone marrow aspirate and core biopsy with the Serum monoclonal protein levels. Where the Bone marrow plasmacytosis is greater than or equal to 10% and the Serum monoclonal protein, g/dL is greater than or equl to 3, the resulant risk will be high. Whereas when the Bone marrow plasmacytosis is greater than or equal to 10% but the Serum monoclonal protein, g/dL is less than 3, then the risk is intermediate. When the Bone marrow plasmacytosis is less than 10% and the Serum monoclonal protein, g/dL is greater than or equal to 3, then the risk is low. Note: For patients with Bone marrow plasmacytosis less than 10% and the Serum monoclonal protein, g/dL less than to 3, the criteria for asymptomatic myeloma is not met according to the guidline hence no rules are fired in the app when such a scenario is selected.

Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, Larson DR, Plevak MF, Jelinek DF, Fonseca R, Melton LJ 3rd, Rajkumar SV. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007 Jun 21;356(25):2582-90. PMID:17582068. Kastritis E, Terpos E, et al. Validation of the Novel Criteria for the Definition of Symptomatic Myeloma: A Single Center Experience in 216 Patients with the Previous Diagnosis of Asymptomatic Disease. Blood 2015 126:4251

OBSERVATION.asymptomatic_myeloma_prognosis.v0, EVALUATION.asymptomatic_myeloma_prognosis.v0